100940-65-6

Sandramycin is a high molecular weight, symmetric, cyclic depsipeptide belonging to the quinomycin class produced by Kribbella sp.. Sandramycin has potent antitumour and antibacterial activity, and is thought to act by bis-intercalation of DNA.

sandramycin is a cyclic depsipeptide antibiotic that was first isolated from cultured broth of a nocardioides sp [1].sandramycin is an antitumor antibiotic. sandramycin was closely related to the cyclic depsipeptides luzopeptins a, b, c and d. sandramycin exhibited strong inhibition to the gram-positive organisms bacillus subtilis, staphylococcus aureus and streptococcusfaecalis. its antimicrobial activity paralleled that which was observed for echinomycin and luzopeptin a [1]. sandramycin was also a bifunctional dna intercalator that strongly binds dna and forms crosslinks between dna molecules [2].in transplantable mouse leukemia p388, sandramycin was moderately active with values comparable to those for luzopeptin a. injection of 2 mg/kg showed the best increase in life span over the controls (61%) [1].

[1]. matson ja, bush ja. sandramycin, a novel antitumor antibiotic produced by a nocardioides sp. production, isolation, characterization and biological properties. j antibiot (tokyo). 1989 dec;42(12):1763-7.
[2]. boger dl, saionz kw. dna binding properties of key sandramycin analogues: systematic examination of the intercalation chromophore. bioorg med chem. 1999 feb;7(2):315-21.